Market Notes: What the Banks, the Chipmakers, and UnitedHealth Told Long-Term Investors This Week

Second-quarter earnings season opened with a heavy week for several widely followed, market-moving companies. Five names we track for these Market Notes reported: JPMorgan Chase (NYSE: JPM) and Goldman Sachs (NYSE: GS) on July 14, ASML (Nasdaq: ASML) on July 15, and Taiwan Semiconductor (NYSE: TSM) and UnitedHealth Group (NYSE: UNH) on July 16. We follow them because they are large, closely watched businesses whose results say something about the wider economy — nothing here is a recommendation to buy or sell any of them (see the disclosure below). Here is what they actually reported, the good and the cautionary alike, read through our usual lens: business quality, durability, and how a long-term investor might think about the news rather than react to it.

What did the big banks' quarters say about the economy?

The two banks posted unusually strong quarters driven by a surge in trading and dealmaking. JPMorgan reported revenue of about $57.8 billion, up 15% year over year, with net income rising roughly 41%; net interest income reached $25.6 billion, and the firm raised its full-year net interest income outlook to about $105.5 billion (The Motley Fool). Equities-trading revenue jumped 86% and investment-banking fees rose 30% to $3.3 billion — figures that reflect an exceptionally active market rather than a permanent run rate. CEO Jamie Dimon called the environment "close to as good as it gets," while also cautioning that market risks are mounting (Benzinga).

Goldman Sachs reported its highest-ever quarterly net revenue of $20.3 billion and net earnings of $6.63 billion, up roughly 78% from a year earlier, with equity underwriting revenue up 130% and its investment-banking backlog at a five-year high (Private Banker International). CEO David Solomon described results as record-setting but "warned of bumps ahead" (BigGo Finance). The useful takeaway for a long-term investor is not the headline beat; it is that both figures were flattered by a boom in trading and capital-markets activity that, by both CEOs' own words, may not persist. Strong quarters built on cyclical tailwinds deserve to be read with that context.

What did the chipmakers signal about AI demand?

TSMC, the world's largest contract chip manufacturer, reported second-quarter revenue of $40.2 billion, up 33.7% year over year, with net income and earnings per share both up about 77% and a gross margin of 67.7% (SEC 6-K filing). Management raised full-year revenue-growth guidance to "slightly above 40%." On the call, CEO C.C. Wei said "our conviction in the multi-year AI megatrend remains very high," and pointed to agentic-AI workloads lifting demand for CPUs alongside AI accelerators (The Motley Fool transcript).

ASML, which supplies the lithography equipment those chips are made on, reported €9.3 billion in net sales and €2.9 billion in net income, with earnings of €7.59 per share and a gross margin of 54.0% (SEC 6-K filing). It nudged up its full-year outlook to €43–45 billion in sales. The counterweight worth noting: expectations for these companies are already high, gross-margin guidance implies some moderation, and a single-quarter demand signal — however strong — is not the same as a guarantee about the next several years. Durable demand and a durably high stock price are different questions.

What stood out in UnitedHealth's report?

UnitedHealth reported second-quarter revenue of $112 billion and adjusted earnings of $6.38 per share, and raised its full-year adjusted earnings guidance to $19.50–$20.00 (SEC 8-K filing). Its medical care ratio improved to 86.7% from 89.4% a year earlier. One honest caveat: about $860 million of net favorable prior-period development helped that ratio, meaning some of the improvement reflects reserve adjustments rather than only current operating performance (Healthcare Finance News). CEO Stephen Hemsley framed the quarter as progress toward "more dependable performance" (The Motley Fool transcript) after a difficult stretch for the company — a reminder that even large, established businesses have rough patches and recoveries.

The bottom line for long-term investors

A cluster of strong reports in a single week can create a pull to act. The more useful discipline is to separate signal from noise: which results reflect durable business strength, and which lean on cyclical activity or one-time items? This week offered both. Trading-fueled bank profits and record chip demand are real, but the executives themselves flagged the caveats — mounting risks, "bumps ahead," high expectations, and favorable reserve development. For long-term investors, quarterly earnings are best used to understand businesses over time, not to time buy-and-sell decisions around a single print.

---

This article is for educational purposes only and does not constitute investment, tax, or legal advice, or a recommendation to buy or sell any security. Consult your financial advisor about your specific situation. Companies mentioned are discussed for educational purposes only; nothing here is a recommendation to buy or sell any security.

Disclosure: One or more of the securities discussed may be held in client accounts managed by VCP Financial. Holdings differ from client to client based on each client's individual objectives and circumstances, are not held by all clients, and are subject to change at any time without notice. The mention of any specific security is not a recommendation to buy, sell, or hold that security, and should not be assumed to be profitable.